Fig. 2

Chemotherapy efficacy and prognosis analysis according to CMTM1_v17 expression pre- and post-chemotherapy in 31 patients. a At the end of NAC, patients with low expression of CMTM1_v17 were sensitive to chemotherapy, with high PR rates compared to those who were CMTM1_v17 high expression (P = 0.008). b Before NAC, there was no significant difference in chemotherapy efficacy in CMTM1_v17 high vs CMTM1_v17 low groups (P = 0.788). These Kaplan-Meier curves illustrate the prognostic significance of CMTM1_v17 pre- and post-NAC in 31 NSCLC patients. c, d At the end of NAC, patients with low expression of CMTM1_v17 had much better prognosis compared to those who were CMTM1_v17 high expression. e, f Before NAC, there was no significant difference in DFS and OS in CMTM1_v17 high vs CMTM1_v17 low groups. OS, overall survival; DFS, disease-free survival; NAC: neoadjuvant chemotherapy